The approval of Valneva’s Corona vaccine is delaying. The European Medicines Agency’s CHMP requested additional data.
Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharma’s imlifidase in anti-GBM disease.
GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
A 3D tumour model developed by scientists enables drug screening in metastases
Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
German Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.